Aarti Industries Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1n6vdmmkepv0kvr9hmrpd49d.pdf

Key Takeaways


Demand & End-Market Conditions

Rajendra Gogri: "General slowdown, that we see from the customer end and everything, that can last about next 2 to 3 quarters, I think that is the broader feedback what we are getting from the customer side."

Long-Term Contracts: Progress & Problems

Rajendra Gogri: "Currently basically, we are looking at slowdown in that even FY24, we don't expect that what we have guided 70% may not happen, so overall we are evaluating under our strategy on that whether we can go downstream or we can try to convert the other line into some other products where we have two different lines in that."

Margin & Profitability Drivers

Rajendra Gogri: "Actually, the value-added product sales will be starting mainly from FY25. So, the impact of the high margin will be coming post FY25. So, slowly the percentage share of this high, more value-added product goes up and overall gross margin at the constant raw material will increase beyond FY25."

Capex & Capacity Expansion

Rajendra Gogri: "It is kind of de-risk us rather than having one single stream plant for us. That is an advantage of sourcing from Deepak Fertilisers compared to our own single plant dependency and second thing, it frees up the cash flow for more on value-added specialized chemistries."

Growth Outlook & Structural Themes

Rajendra Gogri: "FY24 is I think will be more of a turbulent year in that sense. So, that clarity we will be able to give in Q4."

Guidance & Commitments

CommitmentSpecificsTimeline
FY23 EBITDA~₹1,100 crore; not revising, will reshuffle products to meet targetFY23
FY24-FY25 EBITDA CAGR25% CAGR, based on solid business visibilityFY24-FY25
FY25 EBITDA target₹1,700 crore, implying revenue upward of ₹8,500 croreFY25
FY24-FY25 collective capex~₹3,000 croreFY24-FY25
Ethylation & NT commercializationBoth units expected to commercializeH1 FY25
Near-term project commissioningExcept NT and Ethylation, most projects commissionedH1 FY24
Contract one upstream ramp-upUpstream precursors redirected to other markets, ramp to near-full utilizationNext 2 years
Contract two advance phase-outMore than 3 years, annual phase-out a bit lower than 20-25%3+ years
Tax rateExpected to remain lower than 20%Ongoing
Year-end debtExpected around ₹2,600-2,700 croreFY23

Key Metrics

MetricQ3 FY23
Revenue₹1,854 cr, +12% YoY; exports contributed over 48% of total revenues
EBITDA₹289 cr, +26% YoY
Profit after tax₹137 cr
EBITDA margin15.6%, up from 13.9% in Q3 FY22 (per an analyst's math)
Value-added product share81% of total revenue
9M FY23 EBITDA₹837 cr, against full-year guidance of ~₹1,100 cr
FY24–FY25 EBITDA CAGR guidance25%, volume-driven from existing product lines; skewed towards FY25
9M FY23 capex₹840 cr; full-year target ₹1,100–1,200 cr
FY24–FY25 collective capex target₹3,000 cr
FY25 EBITDA target₹1,700 cr
Nitro chlorobenzene production18,199 MT
Nitro-Toluene production7,528 MT; capacity utilization over 90%
Hydrogenation production2,995 TPM
Interim dividend₹1 per share, 20% of face value of ₹5
Gross debt (year-end expected)₹2,600–2,700 cr, gross and net similar